10:43 AM EDT, 04/12/2024 (MT Newswires) -- AbbVie ( ABBV ) said Friday that interim data from an ongoing phase 3 extension study support the long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine.

The company said 70% of the participants experienced at least 50% fewer migraine days each month after 13 to 16 weeks, with the reduction in headaches continuing for nearly a year. No new safety signals were identified, according to the company.

AbbVie ( ABBV ) said it will present the late-breaking interim analysis at an industry conference beginning Saturday in Denver. The open-label extension trial enrolled migraine patients from two prior late-stage studies of atogepant to measure its efficacy and record any negative side effects over three years.

Atogepant has been approved for use in the US and European Union, and is marketed as Qulipta in the US and Aquipta in the EU.

AbbVie ( ABBV ) shares were down 2.3% amid a moderate slide for most stocks on Friday.

Price: 162.11, Change: -3.86, Percent Change: -2.33